APRE
Aprea Therapeutics, Inc.
Price Chart
Latest Quote
$0.71
+0.02 (+2.83%)
Current Price
| Previous Close | $0.69 |
| Open | $0.69 |
| Day High | $0.72 |
| Day Low | $0.65 |
| Volume | 74,522 |
Stock Information
| Shares Outstanding | 12.38M |
| Cash Equivalents | $46.47M |
| Revenue | $123K |
| Net Income | $-11.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.79M |
| EPS (TTM) | $-1.49 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-36.95M |
| Sales | $123K |
| Income | $-11.95M |
| Book/sh | $3.47 |
| Cash/sh | $3.75 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 8.77 |
| Current Ratio | 8.92 |
Returns & Margins
| ROA | -23.18% |
| ROE | -40.40% |
| Operating Margin | -10202.01% |
Ownership
| Insider Ownership | 13.46% |
| Institutional Ownership | 18.13% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.90 |
| P/S | 71.26 |
| P/B | 0.20 |
Analyst Data
| Recommendation | none |
| Target Price | $4.30 |
Technical Indicators
| SMA20 | $0.76 |
| SMA50 | $0.80 |
| SMA200 | $0.94 |
| RSI | 35.70 |
| ATR | 0.0635 |
| Shares Float | 7.41M |
| Short Float | 0.67% |
| Short Ratio | 0.68 |
| Volatility | 1.56 |
| Rel Volume | 0.86 |
Performance History
| Week | -4.77% |
| Month | -2.67% |
| Quarter | -21.86% |
| 6 Months | -21.17% |
| YTD | -16.82% |
| Year | -57.26% |
| 3 Years | -77.69% |
| 5 Years | -99.37% |
| 10 Years | -99.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $0.71 | 74,522 |
| 2026-07-16 | $0.69 | 47,400 |
| 2026-07-15 | $0.70 | 35,900 |
| 2026-07-14 | $0.73 | 145,600 |
| 2026-07-13 | $0.72 | 45,700 |
| 2026-07-10 | $0.75 | 15,400 |
| 2026-07-09 | $0.73 | 43,400 |
| 2026-07-08 | $0.74 | 35,600 |
| 2026-07-07 | $0.77 | 71,000 |
| 2026-07-06 | $0.75 | 72,500 |
| 2026-07-02 | $0.74 | 131,500 |
| 2026-07-01 | $0.75 | 166,400 |
| 2026-06-30 | $0.80 | 107,500 |
| 2026-06-29 | $0.82 | 61,800 |
| 2026-06-26 | $0.79 | 40,500 |
| 2026-06-25 | $0.79 | 23,200 |
| 2026-06-24 | $0.81 | 46,200 |
| 2026-06-23 | $0.83 | 124,300 |
| 2026-06-22 | $0.79 | 373,100 |
| 2026-06-18 | $0.71 | 76,300 |
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
đ° Latest News
Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-07T13:45:17Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-01-30T15:30:19ZNew Strong Sell Stocks for January 19th
Zacks âĸ 2026-01-19T10:14:00Z
New Strong Sell Stocks for Jan. 14
Zacks âĸ 2026-01-14T09:21:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $13,233,836 | $14,319,655 | $15,471,963 | $37,372,044 |
| Other Income Expense | $-17,819 | $71,800 | $-38,926 | $-75,738,650 |
| Other Non Operating Income Expenses | $77,500 | - | - | - |
| Net Non Operating Interest Income Expense | $652,086 | $1,289,144 | $1,224,133 | $448,667 |
| Operating Expense | $13,233,836 | $14,319,655 | $15,471,963 | $37,372,044 |
| Other Operating Expenses | $-285,759 | $-1,502,581 | $-583,231 | - |
| General And Administrative Expense | $6,476,560 | $6,458,699 | $8,427,703 | $20,969,771 |
| Total Other Finance Cost | - | - | - | $-448,667 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Net Interest Income | $652,086 | $1,289,144 | $1,224,133 | $448,667 |
| Interest Income | $652,086 | $1,289,144 | $1,224,133 | $448,667 |
| Normalized Income | $-12,504,250 | $-13,030,511 | $-14,247,830 | $-36,923,377 |
| Net Income From Continuing And Discontinued Operation | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Total Operating Income As Reported | $-13,233,836 | $-14,319,655 | $-15,471,963 | $-113,392,228 |
| Net Income Common Stockholders | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Net Income | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Net Income Including Noncontrolling Interests | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Net Income Continuous Operations | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Pretax Income | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Interest Income Non Operating | $652,086 | $1,289,144 | $1,224,133 | $448,667 |
| Operating Income | $-13,233,836 | $-14,319,655 | $-15,471,963 | $-37,372,044 |
| Special Income Charges | - | - | $0 | $-76,020,184 |
| Per Share | ||||
| Diluted EPS | $-1.93 | $-2.35 | $-3.95 | $-67.99 |
| Basic EPS | $-1.93 | $-2.35 | $-3.95 | $-67.99 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,116,802 | $-14,369,137 | $-15,425,985 | $38,553,051 |
| Total Unusual Items | $-95,319 | $71,800 | $-38,926 | $-75,738,650 |
| Total Unusual Items Excluding Goodwill | $-95,319 | $71,800 | $-38,926 | $-75,738,650 |
| Reconciled Depreciation | $21,715 | $22,318 | $7,052 | $186,445 |
| EBITDA (Bullshit earnings) | $-13,212,121 | $-14,297,337 | $-15,464,911 | $-37,185,599 |
| EBIT | $-13,233,836 | $-14,319,655 | $-15,471,963 | $-37,372,044 |
| Diluted Average Shares | $6,538,722 | $5,509,921 | $3,617,607 | $1,657,055 |
| Basic Average Shares | $6,538,722 | $5,509,921 | $3,617,607 | $1,657,055 |
| Diluted NI Availto Com Stockholders | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Gain On Sale Of Security | $-95,319 | $71,800 | $-38,926 | $281,534 |
| Research And Development | $7,043,035 | $9,363,537 | $7,627,491 | $16,402,273 |
| Selling General And Administration | $6,476,560 | $6,458,699 | $8,427,703 | $20,969,771 |
| Other Gand A | $6,476,560 | $6,458,699 | $8,427,703 | $20,969,771 |
| Other Special Charges | - | - | - | $76,020,184 |
Fetched: 2026-07-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Total Assets | $15,933,401 | $23,979,493 | $22,650,174 | $30,155,827 |
| Total Non Current Assets | $372,155 | $403,354 | $129,079 | $2,321 |
| Other Non Current Assets | $312,348 | $321,832 | $40,717 | - |
| Current Assets | $15,561,246 | $23,576,139 | $22,521,095 | $30,153,506 |
| Other Current Assets | $961,899 | $726,254 | $914,275 | $1,366,859 |
| Cash Cash Equivalents And Short Term Investments | $14,599,347 | $22,849,885 | $21,606,820 | $28,786,647 |
| Cash And Cash Equivalents | $14,599,347 | $22,849,885 | $21,606,820 | $28,786,647 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | $0 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $0 |
| Current Debt And Capital Lease Obligation | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,491,719 | $4,672,038 | $5,696,668 | $4,512,149 |
| Total Non Current Liabilities Net Minority Interest | $727,361 | $1,311,063 | $1,311,063 | $1,311,063 |
| Current Liabilities | $2,764,358 | $3,360,975 | $4,385,605 | $3,201,086 |
| Payables And Accrued Expenses | $1,993,796 | $2,895,960 | $2,839,671 | $1,803,109 |
| Payables | $713,668 | $1,352,240 | $1,670,369 | $842,754 |
| Accounts Payable | $713,668 | $1,352,240 | $1,670,369 | $842,754 |
| Current Deferred Liabilities | - | $0 | $528,974 | $0 |
| Equity | ||||
| Common Stock Equity | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Total Equity Gross Minority Interest | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Stockholders Equity | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Gains Losses Not Affecting Retained Earnings | $-10,634,714 | $-10,627,379 | $-10,611,273 | $-10,623,408 |
| Other Equity Adjustments | $-10,634,714 | $-10,627,379 | $-10,611,273 | $-10,623,408 |
| Retained Earnings | $-333,641,441 | $-321,041,872 | $-308,083,161 | $-293,796,405 |
| Preferred Securities Outside Stock Equity | $727,361 | $1,311,063 | $1,311,063 | $1,311,063 |
| Other | ||||
| Ordinary Shares Number | $8,192,538 | $5,481,055 | $3,736,673 | $2,655,269 |
| Share Issued | $8,192,538 | $5,481,055 | $3,736,673 | $2,655,269 |
| Tangible Book Value | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Invested Capital | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Working Capital | $12,796,888 | $20,215,164 | $18,135,490 | $26,952,420 |
| Total Capitalization | $12,441,682 | $19,307,455 | $16,953,506 | $25,643,678 |
| Additional Paid In Capital | $356,709,645 | $350,971,225 | $335,644,204 | $330,060,836 |
| Capital Stock | $8,192 | $5,481 | $3,736 | $2,655 |
| Common Stock | $8,192 | $5,481 | $3,736 | $2,655 |
| Pensionand Other Post Retirement Benefit Plans Current | $770,562 | $465,015 | $1,016,960 | $1,397,977 |
| Current Accrued Expenses | $1,280,128 | $1,543,720 | $1,169,302 | $960,355 |
| Net PPE | $59,807 | $81,522 | $88,362 | $2,321 |
| Accumulated Depreciation | $-94,155 | $-72,440 | $-50,122 | $-43,070 |
| Gross PPE | $153,962 | $153,962 | $138,484 | $45,391 |
| Other Properties | $148,704 | $148,704 | $133,226 | $40,133 |
| Machinery Furniture Equipment | $5,258 | $5,258 | $5,258 | $5,258 |
| Current Deferred Revenue | - | $0 | $528,974 | $0 |
| Capital Lease Obligations | - | - | - | $0 |
| Long Term Capital Lease Obligation | - | - | - | $0 |
| Current Capital Lease Obligation | - | - | - | $0 |
Fetched: 2026-07-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,894,439 | $-13,572,196 | $-12,270,701 | $-25,011,136 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,894,439 | $-13,556,718 | $-12,177,608 | $-25,011,136 |
| Cash Flow From Continuing Operating Activities | $-12,894,439 | $-13,556,718 | $-12,177,608 | $-25,011,136 |
| Operating Gains Losses | $95,319 | $-71,800 | $38,926 | $-281,534 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-15,478 | $-93,093 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $-15,478 | $-93,093 | $0 |
| Capital Expenditure | - | $-15,478 | $-93,093 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,047,606 | $16,140,356 | $5,788,918 | $682,973 |
| Financing Cash Flow | $4,640,238 | $14,821,895 | $5,139,990 | $682,973 |
| Cash Flow From Continuing Financing Activities | $4,640,238 | $14,821,895 | $5,139,990 | $682,973 |
| Net Other Financing Charges | $-407,459 | $-1,318,461 | $-648,928 | - |
| Net Common Stock Issuance | $5,047,606 | $16,140,356 | $5,788,918 | $682,973 |
| Common Stock Issuance | $5,047,606 | $16,140,356 | $5,788,918 | $682,973 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $14,640,533 | $22,890,055 | $21,647,537 | $28,786,647 |
| Beginning Cash Position | $22,890,055 | $21,647,537 | $28,786,647 | $53,076,052 |
| Effect Of Exchange Rate Changes | $4,679 | $-7,181 | $-8,399 | $38,758 |
| Changes In Cash | $-8,254,201 | $1,249,699 | $-7,130,711 | $-24,328,163 |
| Proceeds From Stock Option Exercised | $91 | $0 | $0 | $0 |
| Net PPE Purchase And Sale | $0 | $-15,478 | $-93,093 | $0 |
| Purchase Of PPE | $0 | $-15,478 | $-93,093 | $0 |
| Change In Working Capital | $-929,095 | $-1,055,396 | $1,618,711 | $-1,758,579 |
| Change In Payables And Accrued Expense | $-711,189 | $-429,748 | $637,743 | $-3,761,963 |
| Change In Accrued Expense | $-64,488 | $-115,541 | $-189,720 | $-2,903,450 |
| Change In Payable | $-646,701 | $-314,207 | $827,463 | $-858,513 |
| Change In Account Payable | $-646,701 | $-314,207 | $827,463 | $-858,513 |
| Change In Prepaid Assets | $-217,906 | $-96,674 | $451,994 | $2,190,086 |
| Other Non Cash Items | $39,050 | $17,435 | - | $72,523,293 |
| Stock Based Compensation | $478,141 | $489,436 | $444,459 | $16,981,266 |
| Depreciation Amortization Depletion | $21,715 | $22,318 | $7,052 | $186,445 |
| Depreciation And Amortization | $21,715 | $22,318 | $7,052 | $186,445 |
| Net Foreign Currency Exchange Gain Loss | $95,319 | $-71,800 | $38,926 | $-281,534 |
| Net Income From Continuing Operations | $-12,599,569 | $-12,958,711 | $-14,286,756 | $-112,662,027 |
| Change In Other Working Capital | - | $-528,974 | $528,974 | - |
| Change In Other Current Liabilities | - | - | $0 | $-186,702 |
| Depreciation | - | - | $7,052 | $186,445 |
Fetched: 2026-07-14